Saturday 17 October 2026
Export MTVA’s income statement to Excel — free account
MetaVia Inc.
MTVA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 68.5% and free cash flow fell 22.4%, each against the same quarter a year earlier.
1.26
0.11
−8.03%
Follow MTVA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.74 | 1.93 | 2.73 | 2.06 |
Net Debt/EBITDA |
4.11 | 5.04 | 3.42 | 2.35 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 2.52 | 1.11 | 0.71 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.33) | (2.75) | (0.88) | (0.63) | |
Cash per Share |
6.43 | 5.82 | 2.83 | 2.13 | |
Shareholders Equity per Share |
2.85 | 3.02 | 1.87 | 1.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.85 | 3.02 | 1.87 | 1.15 | |
Free Cash Flow |
(2.95) | (4.86) | (4.26) | (3.76) | |
Working Capital |
6.21 | 5.23 | 8.97 | 6.72 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
6.21 | 5.09 | 8.85 | 6.62 | |
| Other line items | |||||
Quick Ratio |
1.69 | 1.82 | 2.64 | 1.99 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (2.75) | (0.88) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.19 | 4.86 | 4.72 | 4.68 | |
Average Assets |
18.46 | 13.69 | 13.26 | 15.87 | |
Average Common Equity |
9.64 | 6.63 | 6.73 | 8.22 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates